Awareness of the development of age-related macular degeneration (AMD) has been increasing slowly with the recognition of the advancing age of the population.
Nearly 50% of eyes with wet age-related macular degeneration (AMD) have stable or improved vision after long-term, 8-year pro re nata (PRN) treatment with ranibizumab, according to a group of U.K. clinicians.
An internationally renowned working group of retina specialists, ocular imaging experts, and ocular pathologists have suggested standardizing definitions for age-related macular degeneration (AMD) and its subtypes.
Optometry Australia has developed an AMD chairside reference in consultation with a member-based working group comprised of experienced practitioners.
Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy (GA), the advanced dry form of age-related macular degenerat
Age-related macular degeneration (AMD) is the leading cause of blindness worldwide among the elderly, and its prevalence is expected to increase as the population ages.1
Numerous websites are designed to raise awareness about age-related macular degeneration (AMD), some sponsored by the National Eye Institute (NEI), others by disease-specific foundations, and others by industry.
In age-related macular degeneration (AMD), treat-and-extend regimens, along with the treat-extend-stop (TES) protocol, have shown comparable efficacy to fixed dosing.
Ongoing treatment with anti-vascular endothelial growth factor (VEGF) injections or photodynamic therapy (verteporfin) is, to date, the primary means of managing and treating AMD.
With no “cure,” neovascular age-related macular degeneration (or wet AMD) remains a key disease state for numerous pharmaceutical companies.